Cyclopia extracts act as ERα antagonists and ERβ agonists, in vitro and in vivo

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Visser, Koch ^a   Mortimer, Morné ^a   Louw, Ann ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPIA GENISTOIDES EXTRACT; CYCLOPIA SUBTERNATA EXTRACT; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; P 104; PLANT EXTRACT; SM 6MET; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; CYCLOPIA (GENUS); CYCLOPIA GENISTOIDES; CYCLOPIA SUBTERNATA; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR GENETICS; NONHUMAN; RAT; TEA; TRANSACTIVATION; TRANSREPRESSION; UTERUS GROWTH;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FABACEAE; FEMALE; GENISTEIN; HUMANS; LUCIFERASES; MCF-7 CELLS; NF-KAPPA B; PHYTOESTROGENS; PLANT EXTRACTS; PROMOTER REGIONS, GENETIC; RATS; RATS, WISTAR; SPECIES SPECIFICITY; UTERUS; VAGINA;

EID: 84892411244     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079223     Document Type: Article

References (143)

1. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. JNCI. J Natl Cancer Inst 92: 328-332. doi:10.1093/jnci/92.4.328. PubMed: 10675382.
2. Burger HG, Hale GE, Dennerstein L, Robertson DM (2008) Cycle and hormone changes during perimenopause: The key role of ovarian function. Menopause 15: 603-612. doi:10.1097/gme.0b013e318174ea4d. PubMed: 18574431.
3. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG (2000) A prospective population-based study of menopausal symptoms. Obstet Gynecol 96: 351-358. doi:10.1016/S0029-7844(00)00930-3. PubMed: 10960625.
4. Lindsay R (1996) The menopause and osteoporosis. Obstet Gynecol 87: 16S-19S. doi:10.1016/0029-7844(95)00430-0. PubMed: 8559548.
5. Million women study collaborators (2003) Breast cancer and hormonereplacement therapy in the million women study. The Lancet 362: 419-427
6. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA 288: 321-333. doi:10.1001/jama.288.3.321. PubMed: 12117397.
7. Nand SL, Webster MA, Baber R, O'Connor V (1998) Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. the Ogen/Provera study group. Obstet Gynecol 91: 678-684. doi:10.1016/S0029-7844(98) 00038-6. PubMed: 9572210.
8. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The women's health initiative randomized controlled trial. JAMA 291: 1701-1712. doi:10.1001/jama.291.14.1701. PubMed: 15082697.
9. Lerner LJ, Jordan VC (1990) Development of antiestrogens and their use in breast cancer: Eighth cain memorial award lecture. Cancer Res 50: 4177-4189. PubMed: 2194650.
10. Jordan VC (1988) Chemosuppression of breast cancer with tamoxifen: Laboratory evidence and future clinical investigations. Cancer Invest 6: 589-595. doi:10.3109/07357908809082124. PubMed: 3063338.
11. Hillisch A, Peters O, Kosemund D, Müller G, Walter A et al. (2004) Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Mol Endocrinol 18: 1599-1609. doi:10.1210/me.2004-0050. PubMed: 15105439.
12. Habel LA, Stanford JL (1993) Hormone receptors and breast cancer. Epidemiol Rev 15: 209-219. PubMed: 8405205.
13. Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR et al. (2004) Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: Distinct and common target genes for these receptors. Endocrinology 145: 3473-3486. doi:10.1210/en.2003-1682. PubMed: 15033914.
14. Hertrampf T, Seibel J, Laudenbach U, Fritzemeier KH, Diel P (2008) Analysis of the effects of oestrogen receptor alpha (ERalpha)- and ERbeta-selective ligands given in combination to ovariectomized rats. Br J Pharmacol 153: 1432-1437. PubMed: 18246095.
15. Paruthiyil S, Cvoro A, Zhao X, Wu Z, Sui Y et al. (2009) Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. PLOS ONE 4: e6271. doi:10.1371/journal.pone.0006271. PubMed: 19609440.
16. Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 348: 618-629. doi:10.1056/NEJMra022219. PubMed: 12584371.
17. Tee MK, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J et al. (2004) Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Cell Biol 15: 1262-1272. PubMed: 14699072.
18. Ball LJ, Levy N, Zhao X, Griffin C, Tagliaferri M et al. (2009) Cell typeand estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements. Mol Cell Endocrinol 299: 204-211. doi:10.1016/j.mce.2008.10.050. PubMed: 19059307.
19. Mersereau JE, Levy N, Staub RE, Baggett S, Zogovic T et al. (2008) Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol 283: 49-57. doi:10.1016/j.mce.2007.11.020. PubMed: 18177995.
20. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW et al. (1993) The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329: 1141-1146. doi:10.1056/NEJM199310143291601. PubMed: 8377776.
21. Rymer J, Wilson R, Ballard K (2003) Making decisions about hormone replacement therapy. BMJ 326: 322-326. doi:10.1136/bmj.326.7384.322. PubMed: 12574048.
22. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL et al. (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64: 423-428. doi:10.1158/0008-5472.CAN-03-2446. PubMed: 14729654.
23. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R et al. (1999) Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91: 1131-1137. doi:10.1093/jnci/91.13. 1131. PubMed: 10393721.
24. Cvoro A, Paruthiyil S, Jones JO, Tzagarakis-Foster C, Clegg NJ et al. (2007) Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract. Endocrinology 148: 538-547. PubMed: 17095596.
25. Flötotto T, Niederacher D, Hohmann D, Heimerzheim T, Dall P et al. (2004) Molecular mechanism of estrogen receptor (ER)alpha-specific, estradiol-dependent expression of the progesterone receptor (PR) Bisoform. J Steroid Biochem Mol Biol 88: 131-142. doi:10.1016/j.jsbmb.2003.11.004. PubMed: 15084345.
26. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647. doi:10.1056/NEJM199712043372301. PubMed: 9385122.
27. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA et al. (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852-856. doi:10.1056/NEJM199203263261302. PubMed: 1542321.
28. D'Amelio P, Isaia GC (2013) The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother 14: 949-956. doi:10.1517/14656566.2013. 782002. PubMed: 23521229.
29. Jordan VC (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7: 46-53. doi:10.1038/nrc2048. PubMed: 17186017.
30. Jordan VC, O'Malley BW (2007) Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 25: 5815-5824. doi:10.1200/JCO.2007.11.3886. PubMed: 17893378.
31. MacGregor JI, Jordan VC (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50: 151-196. PubMed: 9647865.
32. O'Regan RM, Jordan VC (2002) The evolution of tamoxifen therapy in breast cancer: Selective oestrogen-receptor modulators and downregulators. Lancet Oncol 3: 207-214. doi:10.1016/S1470-2045(02)00711-8. PubMed: 12067682.
33. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282: 637-645. doi:10.1001/jama.282.7.637. PubMed: 10517716.
34. Cranney A, Adachi JD (2005) Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf 28: 721-730. doi:10.2165/00002018- 200528080-00006. PubMed: 16048357.
35. Fong CJ, Burgoon LD, Williams KJ, Jones AD, Forgacs AL et al. (2010) Effects of tamoxifen and ethynylestradiol cotreatment on uterine gene expression in immature, ovariectomized mice. J Mol Endocrinol 45: 161-173. doi:10.1677/JME-09-0158. PubMed: 20628019.
36. Vosse M, Renard F, Coibion M, Neven P, Nogaret JM et al. (2002) Endometrial disorders in 406 breast cancer patients on tamoxifen: The case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol 101: 58-63. doi:10.1016/S0301-2115(01)00516-4. PubMed: 11803101.
37. Ali S, Coombes RC (2000) Estrogen receptor alpha in human breast cancer: Occurrence and significance. J Mammary Gland Biol Neoplasia 5: 271-281. doi:10.1023/A:1009594727358. PubMed: 14973389.
38. Saji S, Jensen EV, Nilsson S, Rylander T, Warner M et al. (2000) Estrogen receptors alpha and beta in the rodent mammary gland. Proc Natl Acad Sci U S A 97: 337-342. doi:10.1073/pnas.97.1.337. PubMed: 10618419.
39. Chang EC, Frasor J, Komm B, Katzenellenbogen BS (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147: 4831-4842. doi:10.1210/en.2006-0563. PubMed: 16809442.
40. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F (2001) ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142: 4120-4130. doi:10.1210/en.142.9.4120. PubMed: 11517191.
41. Shaaban AM, O'Neill PA, Davies MP, Sibson R, West CR et al. (2003) Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 27: 1502-1512. doi:10.1097/00000478- 200312000-00002. PubMed: 14657709.
42. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J et al. (2004) Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 101: 1566-1571. doi:10.1073/pnas.0308319100. PubMed: 14745018.
43. Lattrich C, Stegerer A, Häring J, Schüler S, Ortmann O et al. (2013) Estrogen receptor beta agonists affect growth and gene expression of human breast cancer cell lines. Steroids 78: 195-202. doi:10.1016/j.steroids. 2012.10.014. PubMed: 23153457.
44. Enmark E, Gustafsson JA (1999) Oestrogen receptors - an overview. J Intern Med 246: 133-138. doi:10.1046/j.1365-2796.1999.00545.x. PubMed: 10447781.
45. Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S et al. (2003) Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem 90: 315-326. doi:10.1002/jcb.10633. PubMed: 14505348.
46. Powell E, Xu W (2008) Intermolecular interactions identify ligandselective activity of estrogen receptor alpha/beta dimers. Proc Natl Acad Sci U S A 105: 19012-19017. doi:10.1073/pnas.0807274105. PubMed: 19022902.
47. Tremblay A, Tremblay GB, Labrie F, Giguère V (1999) Ligandindependent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 3: 513-519. doi:10.1016/S1097-2765(00)80479-7. PubMed: 10230404.
48. Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Wärri A et al. (2002) Estrogen receptor beta in breast cancer. Endocr Relat Cancer 9: 1-13. doi:10.1677/erc.0.0090001. PubMed: 11914179.
49. Williams C, Edvardsson K, Lewandowski SA, Ström A, Gustafsson JA (2008) A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27: 1019-1032. doi:10.1038/sj.onc.1210712. PubMed: 17700529.
50. Wardell SE, Nelson ER, Chao CA, McDonnell DP (2013) Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: Implications for treatment of advanced disease. Clin Cancer Res 19: 2420-2431. doi:10.1158/1078-0432.CCR-12-3771. PubMed: 23536434.
51. Yeh WL, Shioda K, Coser KR, Rivizzigno D, McSweeney KR et al. (2013) Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor alpha protein in MCF-7 cells require the CSK c-src tyrosine kinase. PLOS ONE 8: e60889. doi:10.1371/journal.pone.0060889. PubMed: 23593342.
52. Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA et al. (2008) Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 180: 630-636. PubMed: 18097065.
53. Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA et al. (2002) Antagonists selective for estrogen receptor alpha. Endocrinology 143: 941-947. doi:10.1210/en.143.3.941. PubMed: 11861516.
54. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA et al. (2003) Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol 206: 13-22. doi:10.1016/S0303-7207(03) 00255-7. PubMed: 12943986.
55. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS et al. (2001) Estrogen receptor-beta potency-selective ligands: Structureactivity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 44: 4230-4251. doi:10.1021/jm010254a. PubMed: 11708925.
56. Harris HA (2007) Estrogen receptor-beta: Recent lessons from in vivo studies. Mol Endocrinol 21: 1-13. PubMed: 16556737.
57. Malamas MS, Manas ES, McDevitt RE, Gunawan I, Xu ZB et al. (2004) Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem 47: 5021-5040. doi:10.1021/jm049719y. PubMed: 15456246.
58. Brzezinski A, Debi A (1999) Phytoestrogens: The "natural" selective estrogen receptor modulators? Eur J Obstet Gynecol Reprod Biol 85: 47-51. doi:10.1016/S0301-2115(98)00281-4. PubMed: 10428321.
59. Tikkanen MJ, Adlercreutz H (2000) Dietary soy-derived isoflavone phytoestrogens. could they have a role in coronary heart disease prevention? Biochem Pharmacol 60: 1-5. doi:10.1016/S0006-2952(99)00409-8. PubMed: 10807939.
60. Oseni T, Patel R, Pyle J, Jordan VC (2008) Selective estrogen receptor modulators and phytoestrogens. Planta Med 74: 1656-1665. doi:10.1055/s-0028- 1088304. PubMed: 18843590.
61. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH et al. (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252-4263. doi:10.1210/en.139.10.4252. PubMed: 9751507.
62. Verhoog NJD, Joubert E, Louw A (2007) Screening of four Cyclopia (honeybush) species for putative phyto-oestrogenic activity by oestrogen receptor binding assays. S Afr J Sci 103: 13-21.
63. Verhoog NJ, Joubert E, Louw A (2007) Evaluation of the phytoestrogenic activity of Cyclopia genistoides (honeybush) methanol extracts and relevant polyphenols. J Agric Food Chem 55: 4371-4381. doi:10.1021/jf063588n. PubMed: 17461595.
64. Glazier MG, Bowman MA (2001) A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med 161: 1161-1172. doi:10.1001/archinte.161.9.1161. PubMed: 11343439.
65. Trock BJ, Hilakivi-Clarke L, Clarke R (2006) Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 98: 459-471. doi:10.1093/jnci/djj102. PubMed: 16595782.
66. Kies P (1951) Revision of the genus Cyclopia and notes on some other sources of bush tea. Bothalia 6: 161-176.
67. du Toit J, Joubert E, Britz TJ (1998) Honeybush tea: A rediscovered indigenous South African herbal tea. J Sustain Agric 12: 67-84. doi:10.1300/J064v12n02-06.
68. Mfenyana C, DeBeer D, Joubert E, Louw A (2008) Selective extraction of Cyclopia for enhanced in vitro phytoestrogenicity and benchmarking against commercial phytoestrogen extracts. J Steroid Biochem Mol Biol 112: 74-86. doi:10.1016/j.jsbmb.2008.08.005. PubMed: 18793725.
69. Kamara BI, Brandt EV, Ferreira D, Joubert E (2003) Polyphenols from honeybush tea (Cyclopia intermedia). J Agric Food Chem 51: 3874-3879. doi:10.1021/jf0210730. PubMed: 12797758.
70. Kamara BI, Brand DJ, Brandt EV, Joubert E (2004) Phenolic metabolites from honeybush tea (Cyclopia subternata). J Agric Food Chem 52: 5391-5395. doi:10.1021/jf040097z. PubMed: 15315375.
71. Louw A, Joubert E, Visser K (2013) Phytoestrogenic potential of Cyclopia extracts and polyphenols. Planta Med 79: 580-590. doi:10.1055/s-0032-1328463. PubMed: 23609108.
72. Joubert E, Gelderblom WC, Louw A, de Beer D (2008) South african herbal teas: Aspalathus linearis, Cyclopia spp. and Athrixia phylicoides - A review. J Ethnopharmacol 119: 376-412. doi:10.1016/j.jep.2008.06.014. PubMed: 18621121.
73. Primiano T, Yu R, Kong AT (2001) Signal transduction events elicited by natural products that function as cancer chemopreventive agents. Pharm Biol 39: 83. doi:10.1076/phbi.39.2.83.6256.
74. Lee SO, Nadiminty N, Wu XX, Lou W, Dong Y et al. (2005) Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res 65: 3487-3492. PubMed: 15833885.
75. de Beer D, Schulze AE, Joubert E, de Villiers A, Malherbe CJ et al. (2012) Food ingredient extracts of Cyclopia subternata (honeybush): Variation in phenolic composition and antioxidant capacity. Molecules 17: 14602-14624. doi:10.3390/molecules171214602. PubMed: 23222906.
76. Villalobos M, Olea N, Brotons JA, Olea-Serrano MF, Ruiz de Almodovar JM et al. (1995) The E-screen assay: A comparison of different MCF7 cell stocks. Environ Health Perspect 103: 844-850. doi:10.1289/ehp.95103844. PubMed: 7498097.
77. Flouriot G, Brand H, Denger S, Metivier R, Kos M et al. (2000) Identification of a new isoform of the human estrogen receptor-alpha (hERα) that is encoded by distinct transcripts and that is able to repress hERα activation function 1. EMBO J 19: 4688-4700. doi:10.1093/emboj/19. 17.4688. PubMed: 10970861.
78. Denger S, Reid G, Brand H, Kos M, Gannon F (2001) Tissue-specific expression of human ERα and ERβ in the male. Mol Cell Endocrinol 178: 155-160. doi:10.1016/S0303-7207(01)00417-8. PubMed: 11403905.
79. Hall JM, McDonnell DP, Korach KS (2002) Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol Endocrinol 16: 469-486. doi:10.1210/me.16.3.469. PubMed: 11875105.
80. Plaisance S, Vanden Berghe W, Boone E, Fiers W, Haegeman G (1997) Recombination signal sequence binding protein jkappa is constitutively bound to the NF-kappaB site of the interleukin-6 promoter and acts as a negative regulatory factor. Mol Cell Biol 17: 3733-3743. PubMed: 9199307.
81. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254. doi: 10.1016/0003-2697(76)90527-3. PubMed: 942051.
82. Kanno J, Onyon L, Haseman J, Fenner-Crisp P, Ashby J et al. (2001) The OECD program to validate the rat uterotrophic bioassay to screen compounds for in vivo estrogenic responses: Phase 1. Environ Health Perspect 109: 785-794. doi:10.1289/ehp.01109785. PubMed: 11564613.
83. de Lima; Toccafondo Vieira M, Duarte RF, Campos LM, Nunan Ede A (2008) Comparison of the estrogenic potencies of standardized soy extracts by immature rat uterotrophic bioassay. Phytomedicine 15: 31-37. doi:10.1016/j.phymed.2007. 06.006. PubMed: 17689940. doi:10.1016/j.phymed.2007.06.006 PubMed: 17689940
84. Duncan AM, Phipps WR, Kurzer MS (2003) Phyto-oestrogens. Best Pract Res Clin Endocrinol Metab 17: 253-271. doi:10.1016/S1521-690X(02)00103-3. PubMed: 12787551.
85. Murkies AL, Wilcox G, Davis SR (1998) Clinical review 92: Phytoestrogens. J Clin Endocrinol Metab 83: 297-303. doi:10.1210/jc.83.2.297. PubMed: 9467531.
86. Schreurs R, Lanser P, Seinen W, van der Burg B (2002) Estrogenic activity of UV filters determined by an in vitro reporter gene assay and an in vivo transgenic zebrafish assay. Arch Toxicol 76: 257-261. doi:10.1007/s00204-002- 0348-4. PubMed: 12107642.
87. Kulling SE, Lehmann L, Metzler M (2002) Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens. J Chromatogr B Anal Technol Biomed Life Sci 777: 211-218. doi:10.1016/S1570-0232(02)00215-5. PubMed: 12270214.
88. Riggs BL, Khosla S, Melton LJ 3rd (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23: 279-302. doi:10.1210/er.23.3.279. PubMed: 12050121.
89. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J et al. (2001) Mechanisms of estrogen action. Physiol Rev 81: 1535-1565. PubMed: 11581496.
90. Romas E, Martin TJ (1997) Cytokines in the pathogenesis of osteoporosis. Osteoporos Int 7 Suppl 3: S47-S53. doi:10.1007/BF03194342. PubMed: 9536302.
91. Cacquevel M, Lebeurrier N, Chéenne S, Vivien D (2004) Cytokines in neuroinflammation and alzheimer's disease. Curr Drug Targets 5: 529-534. doi:10.2174/1389450043345308. PubMed: 15270199.
92. Pacifici R (1996) Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11: 1043-1051. PubMed: 8854239.
93. Cao Y, Karin M (2003) NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 8: 215-223. doi:10.1023/A:1025905008934. PubMed: 14635796.
94. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? hopes and pitfalls. Nat Rev Drug Discov 8: 33-40. doi:10.1038/nrd2781. PubMed: 19116625.
95. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140: 883-899. doi:10.1016/j.cell.2010.01.025. PubMed: 20303878.
96. Libermann TA, Baltimore D (1990) Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10: 2327-2334. PubMed: 2183031.
97. Shirakawa F, Mizel SB (1989) In vitro activation and nuclear translocation of NF-kappa B catalyzed by cyclic AMP-dependent protein kinase and protein kinase C. Mol Cell Biol 9: 2424-2430. PubMed: 2548081.
98. Nicholson RI, McClelland RA, Robertson JF, Gee JM (1999) Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 6: 373-387. doi:10.1677/erc.0.0060373. PubMed: 10516852.
99. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A et al. (1987) Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428. doi:10.1016/0092-8674(87)90193-0. PubMed: 2879636.
100. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144: 646-674. doi:10.1016/j.cell.2011.02.013. PubMed: 21376230.
101. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS (2002) Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 143: 4172-4177. doi:10.1210/en.2002- 220403. PubMed: 12399409.
102. Odum J, Lefevre PA, Tittensor S, Paton D, Routledge EJ et al. (1997) The rodent uterotrophic assay: Critical protocol features, studies with nonyl phenols, and comparison with a yeast estrogenicity assay. Regul Toxicol Pharmacol 25: 176-188. doi:10.1006/rtph.1997.1100. PubMed: 9185893.
103. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741. doi:10.1001/jama.295.23. joc60074. PubMed: 16754727.
104. Schmidt C (2010) Third-generation SERMs may face uphill battle. J Natl Cancer Inst 102: 1690-1692. doi:10.1093/jnci/djq477. PubMed: 21060064.
105. Hall J, McDonnell D (2008) Selective estrogen receptor modulators: From bench, to bedside, and back again. Menopausal Med 16.
106. Maximov PY, Lee TM, Jordan VC (2013) The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr. Clin Pharmacol 8: 135-155.
107. Hiroi H, Tsutsumi O, Momoeda M, Takai Y, Osuga Y et al. (1999) Differential interactions of bisphenol A and 17beta-estradiol with estrogen receptor alpha (ERalpha) and ERbeta. Endocr J 46: 773-778. doi:10.1507/endocrj. 46.773. PubMed: 10724352.
108. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK et al. (2000) Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74: 311-317. doi:10.1016/S0960-0760(00)00108-4. PubMed: 11162939.
109. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD et al. (2009) Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 69: 8918-8925. doi:10.1158/0008-5472.CAN-09-2608. PubMed: 19920189.
110. Safe S, Kim K (2008) Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 41: 263-275. doi:10.1677/JME-08-0103. PubMed: 18772268.
111. Scafonas A, Reszka AA, Kimmel DB, Hou XS, Su Q et al. (2008) Agonist-like SERM effects on ERalpha-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterus. J Steroid Biochem Mol Biol 110: 197-206. doi:10.1016/j.jsbmb.2007.10.013. PubMed: 18508261.
112. Gruber CJ, Gruber DM, Gruber IM, Wieser F, Huber JC (2004) Anatomy of the estrogen response element. Trends Endocrinol Metab 15: 73-78. doi:10.1016/j.tem.2004.01.008. PubMed: 15036253.
113. Galien R, Garcia T (1997) Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res 25: 2424-2429. doi:10.1093/nar/25.12.2424. PubMed: 9171095.
114. Ray P, Ghosh SK, Zhang DH, Ray A (1997) Repression of interleukin-6 gene expression by 17 beta-estradiol: Inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett 409: 79-85. doi:10.1016/S0014-5793(97)00487-0. PubMed: 9199508.
115. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS et al. (2006) Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 21: 555-564. doi:10.1016/j.molcel.2006.01. 014. PubMed: 16483936.
116. Gosselin D, Rivest S (2011) Estrogen receptor transrepresses brain inflammation. Cell 145: 495-497. doi:10.1016/j.cell.2011.04.018. PubMed: 21565607.
117. Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR, Karathanasis SK (2000) The role of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in HepG2 cells. Endocrinology 141: 3403-3411. doi: 10.1210/en.141.9.3403. PubMed: 10965913.
118. Nettles KW, Gil G, Nowak J, Métivier R, Sharma VB et al. (2008) CBP is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor. Mol Endocrinol 22: 263-272. PubMed: 17932106.
119. Ghisletti S, Meda C, Maggi A, Vegeto E (2005) 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Mol Cell Biol 25: 2957-2968. doi:10.1128/MCB.25.8.2957-2968.2005. PubMed: 15798185.
120. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103: 843-852. doi:10.1016/S0092-8674(00)00188-4. PubMed: 11136970.
121. Nettles KW, Greene GL (2005) Ligand control of coregulator recruitment to nuclear receptors. Annu Rev Physiol 67: 309-333. doi:10.1146/annurev.physiol. 66.032802.154710. PubMed: 15709961.
122. Hall JM, Couse JF, Korach KS (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276: 36869-36872. doi:10.1074/jbc.R100029200. PubMed: 11459850.
123. Aronica SM, Kraus WL, Katzenellenbogen BS (1994) Estrogen action via the cAMP signaling pathway: Stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A 91: 8517-8521. doi:10.1073/pnas.91.18. 8517. PubMed: 8078914.
124. Powell E, Shanle E, Brinkman A, Li J, Keles S et al. (2012) Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERalpha and ERbeta. PLOS ONE 7: e30993. doi:10.1371/journal.pone.0030993. PubMed: 22347418.
125. Chen X, Garner SC, Quarles LD, Anderson JJ (2003) Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. J Nutr Biochem 14: 342-349. doi:10.1016/S0955-2863(03)00056-1. PubMed: 12873716.
126. Choi EM (2012) Liquiritigenin isolated from glycyrrhiza uralensis stimulates osteoblast function in osteoblastic MC3T3-E1 cells. Int Immunopharmacol 12: 139-143. doi:10.1016/j.intimp.2011.11.003. PubMed: 22116056.
127. Helguero LA, Faulds MH, Gustafsson JA, Haldosén LA (2005) Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24: 6605-6616. doi:10.1038/sj.onc.1208807. PubMed: 16007178.
128. Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE et al. (2003) Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 144: 4241-4249. doi:10.1210/en.2003-0550. PubMed: 14500559.
129. Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468. doi:10.1126/science.1068537. PubMed: 11923541.
130. Gronemeyer H, Gustafsson JA, Laudet V (2004) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3: 950-964. doi:10.1038/nrd1551. PubMed: 15520817.
131. Li H, Huang J, Yang B, Xiang T, Yin X et al. (2013) Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and betacatenin signaling pathway. Toxicol Appl Pharmacol.
132. Han DH, Denison MS, Tachibana H, Yamada K (2002) Relationship between estrogen receptor-binding and estrogenic activities of environmental estrogens and suppression by flavonoids. Biosci Biotechnol Biochem 66: 1479-1487. doi:10.1271/bbb.66.1479. PubMed: 12224631.
133. Zhu JT, Choi RC, Chu GK, Cheung AW, Gao QT et al. (2007) Flavonoids possess neuroprotective effects on cultured pheochromocytoma PC12 cells: A comparison of different flavonoids in activating estrogenic effect and in preventing beta-amyloid-induced cell death. J Agric Food Chem 55: 2438-2445. doi:10.1021/jf063299z. PubMed: 17323972.
134. Collins-Burow BM, Burow ME, Duong BN, McLachlan JA (2000) Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms. Nutr Cancer 38: 229-244. doi:10.1207/S15327914NC382-13. PubMed: 11525602.
135. Setchell KD, Brown NM, Zimmer-Nechemias L, Brashear WT, Wolfe BE et al. (2002) Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr 76: 447-453. PubMed: 12145021.
136. Németh K, Plumb GW, Berrin JG, Juge N, Jacob R et al. (2003) Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur J Nutr 42: 29-42. doi:10.1007/s00394-003-0397-3. PubMed: 12594539.
137. Tu SH, Ho CT, Liu MF, Huang CS, Chang HW et al. (2013) Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression. Food Chem 141: 1553-1561. doi:10.1016/j.foodchem.2013.04.077. PubMed: 23790951.
138. Slavin JL, Karr SC, Hutchins AM, Lampe JW (1998) Influence of soybean processing, habitual diet, and soy dose on urinary isoflavonoid excretion. Am J Clin Nutr 68: 1492S-1495S. PubMed: 9848522.
139. Friend DR, Chang GW (1984) A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J Med Chem 27: 261-266. doi:10.1021/jm00369a005. PubMed: 6699871.
140. Hiremath SP, Badami S, Hunasagatta SK, Patil SB (2000) Antifertility and hormonal properties of flavones of striga orobanchioides. Eur J Pharmacol 391: 193-197. doi:10.1016/S0014-2999(99)00723-2. PubMed: 10720651.
141. Stroheker T, Chagnon MC, Pinnert MF, Berges R, Canivenc-Lavier MC (2003) Estrogenic effects of food wrap packaging xenoestrogens and flavonoids in female wistar rats: A comparative study. Reprod Toxicol 17: 421-432. doi:10.1016/S0890-6238(03)00044-3. PubMed: 12849853.
142. Snijman PW, Swanevelder S, Joubert E, Green IR, Gelderblom WC (2007) The antimutagenic activity of the major flavonoids of rooibos (Aspalathus linearis): Some dose-response effects on mutagen activation-flavonoid interactions. Mutat Res 631: 111-123. doi:10.1016/j.mrgentox.2007.03.009. PubMed: 17537670.
143. Fong CJ, Burgoon LD, Williams KJ, Forgacs AL, Zacharewski TR (2007) Comparative temporal and dose-dependent morphological and transcriptional uterine effects elicited by tamoxifen and ethynylestradiol in immature, ovariectomized mice. BMC Genomics 8: 151. doi:10.1186/1471-2164-8-151. PubMed: 17555576.